At a glance
- Thymopentin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 447 publications mentioning it, including 46 randomized controlled trials and 111 animal-only studies.
- ClinicalTrials.gov lists 10 registered studies testing it (1 active).
- FDA's adverse event system (FAERS) holds 77 reports mentioning it; 75 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Flexibility-driven design of etoposide derivatives targeting Daam1: a thermodynamics-guided strategy against breast cancer metastasis.
- Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8+ T cells.
- Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance.
- Self-assembly driven nano-salinomycin for high-efficiency cancer immunotherapy by reticulum stress mediated stemness suppression.
- Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study).
- Thymopentin Enhances Antitumor Immunity Through Thymic Rejuvenation and T Cell Functional Reprogramming.
- Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study.
- Novel Hybrid Peptide DEFB126 (1-39)-TP5 Inhibits LPS-Induced Inflammatory Responses and Oxidative Stress by Neutralizing LPS and Blocking the TLR4/MD2-NFκB Signaling Axis.
- Neprilysin regulates the progression of glioblastoma: an in-vitro study using siRNA mediated gene silencing and HDAC1 mediated upregulation of neprilysin in U87 MG cells.
- Thymopentin-integrated self-assembling nanoplatform for enhanced photo-immunotherapy in diabetic wound healing.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 10
- Active
- 1
- With posted results
- 0
Conditions studied
All 10 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 77
- Serious
- 75
- With death outcome
- 17
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.